688217 睿昂基因
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)-0.592-5.744-1.7000.8424.434
总资产报酬率 ROA (%)-0.568-5.385-1.5530.7453.985
投入资产回报率 ROIC (%)-0.585-5.612-1.6360.8134.323

边际利润分析
销售毛利率 (%)78.36475.38174.52873.21160.800
营业利润率 (%)-22.277-27.855-11.730-2.51316.901
息税前利润/营业总收入 (%)-21.367-29.182-12.923-5.07715.361
净利润/营业总收入 (%)-19.198-34.085-10.692-1.86115.536

收益指标分析
经营活动净收益/利润总额(%)58.21838.85330.3761.691124.449
价值变动净收益/利润总额(%)-6.456-7.131-8.750-32.0324.333
营业外收支净额/利润总额(%)0.4402.6680.18530.983-0.323

偿债能力分析
流动比率 (X)18.74513.88312.14211.9676.931
速动比率 (X)17.33512.83211.02110.5446.333
资产负债率 (%)3.5264.4246.6007.32510.375
带息债务/全部投入资本 (%)0.0580.0422.1172.2720.533
股东权益/带息债务 (%)169,927.633233,986.5484,560.1904,222.67418,236.108
股东权益/负债合计 (%)2,737.6212,156.7461,397.6271,236.560833.197
利息保障倍数 (X)-21.18451.81811.0343.534-10.337

营运能力分析
应收账款周转天数 (天)353.645311.992262.349308.851177.977
存货周转天数 (天)371.376312.624303.469298.23698.723